Novavax, Inc. (NVV1.F)

EUR 8.74

(0.66%)

Market Cap (In EUR)

1.4 Billion

Revenue (In EUR)

556.38 Million

Net Income (In EUR)

-545.06 Million

Avg. Volume

6335.00

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.33-23.93
PE
-
EPS
-
Beta Value
2.088
ISIN
US6700024010
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. John Charles Jacobs M.B.A.
Employee Count
-
Website
https://www.novavax.com
Ipo Date
2001-02-01
Details
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.